VBCR - August 2017, Vol 6, No 3

Leslie R. Harrold, MD, Associate Professor, Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, and colleagues sought to determine how rituximab affects outcomes self-reported by patients by analyzing data from a cohort of 667 patients with RA who were enrolled in the US Corrona RA Registry.

Dr van der Heijde observed that MRI improvements in Berlin Spine Scores were sustained in patients with AS and patients with nr-axSpA.

Knee osteoarthritis (OA) affects millions of American adults and is characterized by substantial pain, joint stiffness, and functional limitations.

Overall, 5860 instances of erectile dysfunction were reported during the study; patients with gout had an absolute rate of 193 per every 10,000 person-years for erectile dysfunction (95% confidence interval [CI], 184-202), which corresponded to a relative risk increase of 31% (hazard ratio, 1.31; 95% CI, 1.24-1.40) and excess absolute risk of 0.6% compared with those without gout.

One of the earliest observations of giant-cell arteritis (GCA) occurred in the 10th century when oculist ‘Alī ibn ‘Īsā al-Kahhal noted an association between inflamation of the temporal artery and blindness in his book, Tadhkirat.1 GCA is categorized as a large-vessel vasculitis targeting large- and medium-sized blood vessels, and the most feared complication associated with the disease is visual loss from cranial arteritis.

In this study, the investigators analyzed baseline data from 176 patients with RA enrolled in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in RA cohort study from October 2004 to May 2006.

A recently published report has shown that individually tailored behavioral interventions comprised of motivational counseling and text message reminders may effectively reduce daily sedentary time in patients with rheumatoid arthritis.

Previous research has shown gains in trabecular and cortical compartments of the spine and hip regions with 1 year of monthly subcutaneous romosozumab injections.

As drug pricing for Medicare continues to be debated in Congress, drug manufacturers remain under scrutiny; however, several drug manufacturers (ie, AbbVie, Allergan, Johnson & Johnson, Merck, NovoNordisk) have pledged to contain drug price increases to under 10%.

Page 1 of 2
Results 1 - 10 of 12
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology